|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis.
|
31400638 |
2020 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discrimination of CD4+ T cells that lack CCR7 expression revealed that CCR7- CD4+ memory T cells and effectors are producers of intracellular TNFα, IL-13 and IL-4, particularly in dcSSc.
|
31789272 |
2019 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis.
|
31227855 |
2019 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
How these different cell types interact to contribute to SSc is complicated, and can involve cell-to-cell interactions and communication via cytokines, including transforming growth factor (TGF)-β, interleukin (IL)-6 and IL-4.
|
30430560 |
2019 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The levels of serum IL-35 were positively correlated with IL-4 (P = 0.036) and tended to be positively associated with the frequency of Tregs in SSc patients (P = 0.054).
|
29846790 |
2018 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After anti-CD3/CD28 stimulation, higher levels of IL-2 and IL-4 were observed in SSc patients with lung fibrosis (p = 0.01 and 0.006, respectively), and higher levels of IL-10 (p = 0.04) and IL-4 (p = 0.04) in patients with digital ulcers.
|
29601941 |
2018 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As with animal findings, the frequency of pDCs in the lungs of patients with systemic sclerosis correlated with the severity of lung disease and with the frequency of CD4+ and IL-4+ T cells in the lung.
|
29720568 |
2018 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, Treg cells from skin affected by SSc produced significant amounts of IL-4 and IL-13.
|
25678090 |
2015 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the interleukin 4, interleukin 13, and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression.
|
22045834 |
2012 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TGFbeta, PDGF-B, or IL-4 reduced the levels of miR-29a in normal fibroblasts to those seen in SSc fibroblasts.
|
20201077 |
2010 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Cytokine concentrations in exhaled breath condensates in systemic sclerosis.
|
18351434 |
2008 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the causes of fibrosis in scleroderma are unknown, cytokines such as TGF-beta, IL-4 and IL-13, play a crucial role in the stimulation of collagen production have been implicated in the disease process.
|
16380822 |
2005 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma?
|
16139999 |
2005 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes.
|
14729510 |
2004 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Both wild-type and an alternative splice variant of IL-4 mRNA were increased in BAL cells from SSc patients.
|
10366109 |
1999 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the CAT assay, the percentage of acetylation was 7.0% +/- 2.0% in untreated controls and 12.5% +/- 3.5% in SSc fibroblasts at 5.0 ng/ml of IL-4.
|
8814542 |
1996 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-2, interleukin-4, interleukin-6, and transforming growth factor-beta have been implicated as cytokines that may be involved in the pathogenesis of systemic sclerosis.
|
1457282 |
1992 |